Substance · official US FDA label
Chlorhexidine (chlorhexidine)
10 medicines listed on Vimpia contain it, alone or combined. Below, the official US FDA label for chlorhexidine, unchanged.
Want to buy it?
Trouver shows the pharmacies near you that have it right now, and their prices. The reservation pages are in French.
This is a US label.
The official US FDA label for chlorhexidine (published as CHLORHEXIDINE GLUCONATE ORAL RINSE), effective September 10, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for chlorhexidine
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
INDICATION Chlorhexidine gluconate oral rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate oral rinse has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS .
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
DOSAGE AND ADMINISTRATION Chlorhexidine gluconate oral rinse therapy should be initiated directly following a dental prophylaxis. Patients using chlorhexidine gluconate oral rinse should be reevaluated and given a thorough prophylaxis at intervals no longer than six months. Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after toothbrushing. Usual dosage is 15 mL (marked in cap) of undiluted chlorhexidine gluconate oral rinse. Patients should be instructed to not rinse with water, or other mouthwashes, brush teeth, or eat immediately after using chlorhexidine gluconate oral rinse. Chlorhexidine gluconate oral rinse is not intended for ingestion and should be expectorated after rinsing.
Warnings and precautions
WARNINGS The effect of chlorhexidine gluconate oral rinse on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chlorhexidine gluconate oral rinse users compared with control users. It is not known if chlorhexidine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. SEE CONTRAINDICATIONS .
Side effects
ADVERSE REACTIONS The most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; see WARNINGS and PRECAUTIONS . Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse. The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1%. Among post marketing reports, the most frequently reported oral mucosal symptoms associated with chlorhexidine gluconate oral rinse are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia. Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using chlorhexidine gluconate oral rinse. There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using chlorhexidine gluconate oral rinse.
Medicines that contain it
Names as they are sold. A medicine without an English page links to its French page.
- Chlorhexidine 5%, Solution, gel externe
- Chlorhexidine 7,1%, Solution, gel externe
- Cetrimide + Chlorhexidine 15 % + 1,5 %, Solution (in French)
Combined with other substances
- Cetrimide, Chlorhexidine 15 % p/v/1,5 % p/v, solution topique (in French)
Combined with other substances
- Chlorhexidine + chlorure de benzalkonium 0,2% + 0,5%, Solution (in French)
Combined with other substances
- VORJA CITRON 2 mg/0,5 mg par mL, solution pour pulvérisation buccale édulcorée au sucralose (in French)
Combined with other substances
- VORJA CITRON 5 mg/1 mg, comprimé à sucer édulcoré au sorbitol, à l’aspartame et à l’acésulfame de potassium (in French)
Combined with other substances
- VORJA MENTHOL 2 mg/0,5 mg par mL, solution pour pulvérisation buccale édulcorée à la saccharine sodique (in French)
Combined with other substances
- VORJA MENTHOL 5 mg/1 mg, comprimé à sucer édulcoré au sorbitol (in French)
Combined with other substances
- VORJA MIEL 5 mg/1 mg, comprimé à sucer édulcoré au sorbitol et à la stévia (in French)
Combined with other substances
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Marketing authorizations: register of the ACOREP, DR Congo.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.